Urologic Diseases Clinical Trial
Official title:
Canadian Cohort of Convective Thermal Therapy Using Rezūm System in Benign Prostatic Hyperplasia (BPH).
Verified date | January 2022 |
Source | Can-Am HIFU Inc. |
Contact | Iris Chan |
Phone | 416-603-5800 |
iris.chan2[@]uhn.ca | |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
To document the clinical outcome of Rezūm therapy for BPH patient in Canadian cohort.
Status | Recruiting |
Enrollment | 50 |
Est. completion date | December 31, 2026 |
Est. primary completion date | December 31, 2023 |
Accepts healthy volunteers | No |
Gender | Male |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Male subjects of = 18 years of age. - Primary diagnosis of Benign Prostate Hypertrophy (BPH). - Candidate for Rezum therapy as per clinical decision of Investigator. - Willing and able to accurately complete the required questionnaires. - Willing and able to provide signed and dated informed consent Exclusion Criteria: - Characteristics indicating a poor compliance with study protocol requirements. - Disease or other health condition that is not suitable for this study. - Unable or unwilling to provide signed informed consent. |
Country | Name | City | State |
---|---|---|---|
Canada | Dean Elterman | Toronto | Ontario |
Lead Sponsor | Collaborator |
---|---|
Can-Am HIFU Inc. |
Canada,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Maximum flow rate (Q-max) | Maximum flow rate (Q-max) | Baseline | |
Primary | Change of Maximum flow rate (Q-max) | Change of Maximum flow rate (Q-max) | 1 month after surgery | |
Primary | Change of Maximum flow rate (Q-max) | Change of Maximum flow rate (Q-max) | 3 months after surgery | |
Primary | Change of Maximum flow rate (Q-max) | Change of Maximum flow rate (Q-max) | 6 months after surgery | |
Primary | Change of Maximum flow rate (Q-max) | Change of Maximum flow rate (Q-max) | 12 months after surgery | |
Primary | Change of Maximum flow rate (Q-max) | Change of Maximum flow rate (Q-max) | 24 months after surgery | |
Primary | Change of Maximum flow rate (Q-max) | Change of Maximum flow rate (Q-max) | 36 months after surgery | |
Primary | Post-Void Residual (PVR) volume | Post-Void Residual (PVR) volume | Baseline | |
Primary | Change of Post-Void Residual (PVR) volume | Change of Post-Void Residual (PVR) volume | 1 month after surgery | |
Primary | Change of Post-Void Residual (PVR) volume | Change of Post-Void Residual (PVR) volume | 3 months after surgery | |
Primary | Change of Post-Void Residual (PVR) volume | Change of Post-Void Residual (PVR) volume | 6 months after surgery | |
Primary | Change of Post-Void Residual (PVR) volume | Change of Post-Void Residual (PVR) volume | 12 months after surgery | |
Primary | Change of Post-Void Residual (PVR) volume | Change of Post-Void Residual (PVR) volume | 24 months after surgery | |
Primary | Change of Post-Void Residual (PVR) volume | Change of Post-Void Residual (PVR) volume | 36 months after surgery | |
Primary | Prostate Volume measured by transrectal ultrasound (TRUS) | Prostate Volume measured by transrectal ultrasound (TRUS) | Baseline | |
Primary | Change of Prostate Volume measured by transrectal ultrasound (TRUS) | Change of Prostate Volume measured by transrectal ultrasound (TRUS) | 12 months after surgery | |
Primary | Questionnaire | IPSS | Baseline | |
Primary | Change of Questionnaire | Change of IPSS score | 1 month after surgery | |
Primary | Change of Questionnaire | Change of IPSS score | 3 months after surgery | |
Primary | Change of Questionnaire | Change of IPSS score | 6 months after surgery | |
Primary | Change of Questionnaire | Change of IPSS score | 12 months after surgery | |
Primary | Change of Questionnaire | Change of IPSS score | 24 months after surgery | |
Primary | Change of Questionnaire | Change of IPSS score | 36 months after surgery | |
Primary | Adverse Events | Adverse Events | Baseline | |
Primary | Change of Adverse Events | Change of Adverse Events | 1 month after surgery | |
Primary | Change of Adverse Events | Change of Adverse Events | 3 months after surgery | |
Primary | Change of Adverse Events | Change of Adverse Events | 6 months after surgery | |
Primary | Change of Adverse Events | Change of Adverse Events | 12 months after surgery | |
Primary | Change of Adverse Events | Change of Adverse Events | 24 months after surgery | |
Primary | Change of Adverse Events | Change of Adverse Events | 36 months after surgery |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06397287 -
PROM Project Urology
|
||
Completed |
NCT03572348 -
VeSpAR: Comparing Vessel-Sparing Anastomotic Repair and Transecting Anastomotic Repair in Isolated Short Bulbar Strictures.
|
N/A | |
Completed |
NCT03339609 -
Uroflow Measurement With Electromyography (EMG) to Identify Lower Urinary Tract Symptoms (LUTS): Conducted on Healthy Children
|
N/A | |
Active, not recruiting |
NCT01529658 -
Renal Hypothermia During Partial Nephrectomy
|
N/A | |
Completed |
NCT05082142 -
Tranexamic Acid to Improve Same-day Discharge Rates After Holmium Laser Enucleation of the Prostate (HoLEP)
|
Phase 4 | |
Completed |
NCT03668262 -
ED50 of Cis-atracurium for Laryngeal Mask Incubation in General Anesthesia
|
||
Recruiting |
NCT04763538 -
Quality and Outcome Measurements of Urological Patients
|
||
Not yet recruiting |
NCT03899298 -
Safety and Clinical Outcomes With Amniotic and Umbilical Cord Tissue Therapy for Numerous Medical Conditions
|
Phase 1 | |
Completed |
NCT05032287 -
Medical Expulsive Therapy Post-SWL For Renal Stones
|
N/A | |
Active, not recruiting |
NCT03243682 -
The Alternating Bidirectional Versus The Standard Approach During Shock Wave Lithotripsy For Renal And Upper Lumbar Ureteric Stones
|
N/A | |
Recruiting |
NCT05169892 -
Aquablation in Benign Prostatic Hyperplasia in Canada
|
||
Enrolling by invitation |
NCT03234543 -
Remote Ischemic Conditioning in Abdominal Surgery
|
N/A | |
Recruiting |
NCT06187870 -
Bank of Biological Material From Patients and Healthy Donors for the Study of Urological and Uro-oncological Pathologies
|
||
Completed |
NCT03847909 -
A Study to Evaluate DCR-PHXC in Children and Adults With Primary Hyperoxaluria Type 1 and Primary Hyperoxaluria Type 2
|
Phase 2 | |
Recruiting |
NCT04972890 -
The Outcomes of Intracavernosal Umbilical Cord Mesenchymal Stem Cells Implantation in Patients With Diabetic Erectile Dysfunction
|
Phase 2/Phase 3 | |
Not yet recruiting |
NCT03258658 -
Safety and Feasibility Study of Autologous Engineered Urethral Constructs for the Treatment of Strictures
|
Phase 1 | |
Terminated |
NCT02543645 -
A Study of Varlilumab and Atezolizumab in Patients With Advanced Cancer
|
Phase 1 | |
Terminated |
NCT03843073 -
Connected Catheter- Safety and Effectiveness Study
|
N/A | |
Terminated |
NCT04826484 -
Opioid Reduction Initiative During Outpatient Pediatric Urologic Procedures Using Exparel
|
Phase 3 | |
Terminated |
NCT04059159 -
Connected Catheter - Safety and Effectiveness Study
|
N/A |